Emmes, a global Clinical Research Organization (CRO) committed to advancing public health and biopharmaceutical innovation, has made a game-changing acquisition with the purchase of Essex Management. Essex is a leading provider of bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is a strategic move by Emmes to continue growing its services and offering its clients cutting-edge solutions. With the addition of Essex, Emmes will be able to unlock new opportunities with government agencies and provide innovative data strategies for biopharma clients.
The merger of Emmes and Essex will elevate Emmes to a new level as a full-service clinical research partner with a focus on data-driven solutions. With Essex’s technology expertise and Emmes’ innovative data and advanced analytics solutions, the CRO is better equipped than ever to tackle global health challenges and provide innovative solutions to its clients.
Essex’s reputation as a technology catalyst for life science innovation, combined with Emmes’ long-standing partnerships with the National Cancer Institute (NCI) and other public sector clients, will create a powerhouse combination that will drive growth and advance clinical research.